Public Health Preparedness and Response Newsletters

The FDA coordinates medical countermeasure development, preparedness and response to help protect the United States from chemical, biological, radiological, nuclear, and emerging infectious disease threats.

Stay up-to-date on news, events, reports and more:

• Subscribe: enter your email in the Subscribe box at the bottom of this page to receive FDA public health preparedness and response email updates.
• To subscribe to other FDA emails, visit our subscription management center.
• Bookmark the Public Health Preparedness and Response Newsletter page

Previous editions

2024 | 2023 | 2022 and earlier

Note that links in previous editions may no longer be active.

2025

• January 16, 2025: National Antimicrobial Resistance Monitoring System Strategic Plan and New Supply Chain FDA.gov Content

2024

• December 18, 2024: Hurricane Helene Baxter Recovery, New FDA Guidances, and EUA Updates
• November 20, 2024: HPAI H5N1 Bird Flu Updates | Know When to Use Antibiotics
• October 31, 2024: IV Solutions Supply Increasing; Expiration Date Extensions
• October 16, 2024: IV solution supply chain updates | New at-home flu and COVID-19 test
• October 1, 2024: FDA reorganization effective today | New digital health and AI resource
• September 10, 2024: Medical countermeasure updates: COVID-19 and mpox
• August 20, 2024: Latest HPAI (H5N1) updates from FDA | AI and machine learning update | Clinicians Connect on fall respiratory virus season
• July 23, 2024: Latest HPAI (H5N1) updates from FDA | C. auris test authorized
• June 27, 2024: New medical countermeasures report | Latest HPAI (H5N1) updates from FDA
• June 6, 2024: Platform technology guidance | FDA reorganization update | Latest HPAI (H5N1) updates from FDA
• May 20, 2024: Highly pathogenic avian influenza (H5N1) in dairy cows: National retail dairy product sample results
• May 1, 2024: Highly pathogenic avian influenza (H5N1) in dairy cows | AI and antimicrobial resistance updates
• April 2, 2024: FDA authorizes new long-acting monoclonal antibody for pre-exposure prevention of COVID-19 | New AI paper | Drug shortage updates
• March 5, 2024: FDA works to make informed consent easier to understand | Final guidance on assessing COVID-19 symptoms in clinical trials
• February 12, 2024: Paxlovid expiration date information | Register to attend data quality in BSL-4 labs course

Newsletter archives

• For MCMi newsletters from 2023, please visit this archive page
• For MCMi newsletters from 2022 and earlier, please visit this archive page